Inflammatory and Subclinical Cardiac Phenotypes During Gabapentin or Pregabalin Treatment for Lumbar Radicular Pain: A Prospective Cohort with Human Transcriptomic and Genetic Contextualization
Background: The short-term comparative effects of gabapentin and pregabalin on circulating NLRP3, NF-κB p65, STAT3, and subclinical cardiac phenotypes remain insufficiently characterized. This study examined these outcomes prospectively, with independent human transcriptomic and genetic analyses providing biological context. Methods: Twenty-five gabapentinoid-naive patients initiating gabapentin and 25 initiating pregabalin for chronic lumbar radicular pain associated with MRI-confirmed lumbar disc herniation underwent serum and echocardiographic assessment at baseline and after 30 days. Twenty-five untreated healthy controls were assessed at baseline only. Eleven prespecified endpoints were evaluated using baseline-adjusted ANCOVA with age and sex adjustment, HC3 standard errors, and Benjamini–Hochberg correction. Five prespecified anchor genes (CACNA2D1, CACNA2D2, NLRP3, RELA, and STAT3) were examined across five independent human transcriptomic resources and through prespecified cis-eQTL Mendelian randomization with regional colocalization. Results: No statistically detectable between-treatment difference was identified across the eleven primary endpoints (minimum nominal p = 0.162; minimum adjusted q = 0.728). Transcriptomic findings were tissue and disease dependent: RELA expression was higher in Morton neuroma; CACNA2D2 was higher and STAT3 lower in both cardiomyopathies; and NLRP3 was higher in ischemic cardiomyopathy but not in the other disease contrasts. Epithelial–mesenchymal transition and TNF-α/NF-κB signaling were positively enriched across all three disease contrasts, whereas IL-6–JAK–STAT3 enrichment was not significant in dilated cardiomyopathy. Three estimable Mendelian randomization comparisons involving genetically proxied STAT3 expression showed no statistically detectable association with heart failure or dilated cardiomyopathy. Regional colocalization was uninformative because combined H3 + H4 posterior mass was low (0.024–0.063), limiting discrimination between shared and distinct causal variants. Conclusions: No statistically detectable difference between gabapentin and pregabalin was observed after 30 days in circulating molecular markers or echocardiographic phenotypes; this does not establish therapeutic equivalence. Independent transcriptomic and genetic findings provided complementary biological context without demonstrating treatment-related molecular effects, target engagement, causality, or a therapeutic mechanism.
Authors
- Derya Baykız (ORCID: https://orcid.org/0000-0003-0666-6631)
- Lütfi Çağatay Onar (ORCID: https://orcid.org/0000-0002-7767-9029)
- Merve KABADAYI (ORCID: https://orcid.org/0000-0001-9430-6999)
- Muharrem Furkan Yuzbasi (ORCID: https://orcid.org/0000-0002-2816-6921)
- Tamer Tamdoğan (ORCID: https://orcid.org/0000-0002-0526-1459)
- Sevim Ondul (ORCID: https://orcid.org/0000-0003-4219-4862)
- İbrahim Yılmaz (ORCID: https://orcid.org/0000-0003-2003-6337)
- Gökhan Gök (ORCID: https://orcid.org/0009-0001-9729-6391)
Institutions
- Ministry of Health (TR)
- Giresun University (TR)
- Istanbul University-Cerrahpaşa (TR)
- Kahramanmaraş Sütçü İmam University (TR)
- Istanbul University (TR)
Publication Details
- Journal
- Genes
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3390/genes17111474
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00